Takis is a Rome-based biotechnology company with a stated focus of the research and development of therapeutic cancer vaccines against tumor antigens, which play a role in tumor development and maintenance. It conducts research and develops technology for the sectors of immunology, oncology, infectious diseases, and preclinical models.
The company uses its genetic technology for viruses and DNA fragments that can be harnessed for gene therapy and vaccinations. It is working with another biotechnology company, LineaRx, as well as its own subsidiary, Evvivax, to develop a polymerase chain reaction (PCR)-based DNA (LinearDNA) manufacturing system for a vaccine for COVID-19.
Applied DNA and Takis Biotech Expand COVID-19 Vaccine Development Program to Include 5th Candidate
April 2, 2020
Documentaries, videos and podcasts
Takis NeoMatrix EIT HealthCatapult HD
November 26, 2019
- Cluster: BiotechnologyA cluster of topics related to biotechnology.
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.